Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2

Mahmoud, Sally; Ganesan, Subhashini; Kaabi, Nawal Al; Naik, S V; Elavalli, Santosh; Gopinath, Prem; Ali, Alaa Mousa; Bazzi, Lara; Warren, K N; Zaher, Walid; Housany, Farida Al

doi:10.1016/j.jcv.2022.105161

Cited by 10 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GMTs of neutralizing antibody activities against live SARS-CoV-2 Delta and Omicron variants were measured using plaque reduction neutralization test (PRNT) with the test kits shown in previous study. 19 The peripheral blood mononuclear cells were collected to assess specific T-helper-1(Th1, interferon gamma (IFN-γ) release) and T-helper-2 (Th2, interleukin-4 (IL-4) release) responses before vaccination, and on day 14 after booster vaccination (D14) using T-SPOT Ⓡ .COVID test and enzyme-linked immunospot (ELISpot) IL-4 COVID TEST assay, reported in previous studies. 20 The ELISA IgG test, ELISpot assay and live virus neutralization assay were performed according to the manufacturer's guidelines (Biogenix, Abu Dhabi, United Arab Emirates) at G42 LABORATORY LLC in Abu Dhabi, United Arab Emirates.…”

Section: Methodsmentioning

confidence: 99%

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial

Hannawi¹,

Saifeldin²,

Abuquta³

et al. 2023

eBioMedicine

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial

Hannawi¹,

Saifeldin²,

Abuquta³

et al. 2023

eBioMedicine

View full text Add to dashboard Cite

“…Although neutralizing activity was reduced, inactivated vaccination still produced a better response from memory cells ( 8 ). T-cell responses alleviated disease progression caused by COVID-19 variants ( 17 ).…”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Research has demonstrated that booster doses of the inactive vaccine BBIBP-CORV have better protection against SARS-CoV-2-related variants ( 8 ), and virus-specific antibodies were detected in 91.48% of vaccine participants on Day 28 after the second vaccine dose ( 19 ). Although neutralizing activity is reduced with inactivated vaccination, it still produced a better response from memory cells ( 8 ). T-cell responses alleviated disease progression caused by COVID-19 variants that partially or largely evade neutralizing antibodies, which is in good agreement with T-cell-mediated immunity in humans for influenza ( 17 ).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, lymphocytopenia is associated with severe COVID-19 infection and is correlated with poor prognosis (5)(6)(7). Research has demonstrated that booster doses of the inactive vaccine BBIBP-CORV have better protection against SARS-CoV-2-related variants (8). Ratios of TNF-α-producing CD4 + T lymphocytes were higher in patients vaccinated with inactive vaccines following SARS-CoV-2 antigen stimulation (9).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A diagnostic model for serious COVID-19 infection among older adults in Shanghai during the Omicron wave

Bao

Kang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundThe Omicron variant is characterized by striking infectivity and antibody evasion. The analysis of Omicron variant BA.2 infection risk factors is limited among geriatric individuals and understanding these risk factors would promote improvement in the public health system and reduction in mortality. Therefore, our research investigated BA.2 infection risk factors for discriminating severe/critical from mild/moderate geriatric patients.MethodsBaseline characteristics of enrolled geriatric patients (aged over 60 years) with Omicron infections were analyzed. A logistic regression analysis was conducted to evaluate factors correlated with severe/critical patients. A receiver operating characteristic (ROC) curve was constructed for predicting variables to discriminate mild/moderate patients from severe/critical patients.ResultsA total of 595 geriatric patients older than 60 years were enrolled in this study. Lymphocyte subset levels were significantly decreased, and white blood cells (WBCs) and D-dimer levels were significantly increased with disease progression from a mild/moderate state to a severe/critical state. Univariate and multivariate logistic regression analyses identified a panel of WBCs, CD4+ T cell, and D-dimer values that were correlated with good diagnostic accuracy for discriminating mild/moderate patients from severe/critical patients with an area under the curve of 0.962.ConclusionSome key baseline laboratory indicators change with disease development. A panel was identified for discriminating mild/moderate patients from severe/critical patients, suggesting that the panel could serve as a potential biomarker to enable physicians to provide timely medical services in clinical practice.

show abstract

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial

Hannawi,

Yan,

Saf Eldin

et al. 2023

eClinicalMedicine

View full text Add to dashboard Cite

Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2

Cited by 10 publications

References 16 publications

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial

A diagnostic model for serious COVID-19 infection among older adults in Shanghai during the Omicron wave

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial

Contact Info

Product

Resources

About